Study of the Efficacy and Safety of Ublituximab in Patients With Relapsed or Refractory B-cell Non-Hodgkin Lymphoma

Inclusion Criteria:

Relapsed or Refractory B-cell Lymphoma
Measurable or Evaluable Disease
Previously treated with at least one line of rituximab or a rituximab based therapy
Patients ineligible for high dose or combination chemotherapy + stem cell transplant
Eastern Cooperative Oncology Group (ECOG) Performance Status of 0, 1 or 2
No active or chronic infection of Hepatitis B or C and no history of HIV based on negative serology

Exclusion Criteria:

Prior chemotherapy, investigational therapy or radiotherapy within 3 weeks of study entry
Prior autologous or allogeneic stem cell transplantation within 3 months of study entry
History of severe hypersensitivity or anaphylaxis to prior rituximab
Uncontrolled inter-current illness including, but not limited to, ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, brain metastasis, or psychiatric illness that would limit compliance with study requirements
Pregnant women